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A B S T R A C TAs part of the global trend to address the constrained resources for
population health care coverage, the concepts of pharmacoeconomics
(PE) and health technology assessment (HTA) have been introduced to
Asia in the last decade. Medicines are just one of numerous types of
innovative technologies developed to address unmet medical need.
Many of these medicines receive a great deal of attention because of
their potential impact on limited health care budgets. There are a few
key challenges for using PE and HTA in making informed decisions
regarding the value of a given new health care technology in an Asian
country. These challenges include 1) recognizing the multidimensionalsee front matter Copyright & 2014, International S
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ingford, CT 06492, USA.aspects of PE and HTA, which can include both health care and
political considerations; 2) involving stakeholders (with a focus on
patients) in decision making; 3) balancing short- and long-term overall
beneﬁts of innovative medicines; and 4) giving consideration to speciﬁc
local cultural and health care characteristics.
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pharmaceuticals, pharmacoeconomics, population.
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In 2004, Doherty et al. [1] evaluated the early evolution of
pharmacoeconomics (PE) in Asia, including China, Japan, South
Korea, Hong Kong, Taiwan, and Singapore. On the basis of their
assessments, the authors proposed that controlling health care
expenditure and increasing the efﬁcient use of limited health
care resources were the two most important reasons for applying
PE to health care in Asia. The authors predicted that the need for
PE in Asian health care would result in more academic studies
and consequently increased numbers of publications on this
subject, which would enhance appreciation for the use of PE in
Asia. In these authors’ view, this trend would be so even in the
absence of formal processes for evaluating PE in these countries.
Over the last 8 years since the Doherty et al. article was
published, there has been a rapid advancement in the under-
standing and implementation of PE in Asia. This is evidenced by
many published research articles on the topic. In addition, there
have been many important events related to PE development in
the region, including the establishment of National Evidence-
based Healthcare Collaborating Agency [2,3], which acts as one of
the resources providing information on health economics to
support decision making on pharmaceutical reimbursement by
Health Insurance Review Agency in South Korea [4]. In Taiwan, ahealth technology assessment (HTA) group has been established
within the Center of Drug Evaluations to evaluate pharmaceutical
pricing and reimbursement submission and HTA has been
included as part of the National Act of 2nd Generation of
Healthcare Insurance Reform [5]. In China, PE guidelines have
been published [6] and there is ongoing active academic research
on HTA [7]. In addition, a group of scholars from mainland China,
Taiwan, and Hong Kong created the Greater China (Huaxia)
Forum on Health Economics. In Japan, there is a plan to conduct
a pilot HTA program by the Ministry of Health, Labor and Welfare
[8]. The creation of International Society of Pharmacoeconomics
and Outcomes Research Asia Consortium has greatly fostered the
development of PE in the region. After 8 years since the landmark
article by Doherty et al., PE activities and research are found in
more Asian countries than the originally mentioned in their
article, such as Thailand, Malaysia, India, Indonesia, and the
Philippines [9].
The economy in Asia and the global advancement of innova-
tive medicines have played an important role in pushing the PE
development in the region. In the last two decades, there has
been greater economic growth in Asia than in other parts of the
world. In 2011, health care expenditure as a percentage of gross
domestic product (GDP) was quite high across all Asian countries,
with Japan and South Korea having the highest proportion of GDPociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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signiﬁcant proportion of the GDP, indicating the signiﬁcant
efforts being made by the public sector to provide health care
coverage to citizens in these countries. This effort also likely
reﬂects increased demands on health care due to aging popula-
tions, evolution of disease patterns, and access to improved
health technologies. One particular pressure on health care costs
is the increased number of potential medicines being developed
worldwide. For example, a global statistics showed that by 2011,
the number of new medicines under clinical development ranged
from 96 for antiviral treatments (hepatitis B virus [HBV], hepatitis
C virus [HCV] and HIV) to 1527 for various tumors [11]. Although
not every candidate was or will be successfully developed, a good
number are anticipated to eventually reach Asian markets.
Approvals of these new medicines certainly put pressure on
limited health care resources in these Asian countries.
To revisit the question of “what is next for pharmacoeconom-
ics in Asia” that Doherty et al. asked 8 years ago, this article
discusses key challenges in adopting innovative technologies,
including 1) multidimensional feature of applying PE, 2) stake-
holders’ involvement, 3) patients’ role, 4) focus on overall beneﬁt,
and 5) local adaptation of PE. Among all the challenges, the
critical point will be how the core value of these innovative
medicines should be evaluated in different Asian health care
systems.
While Research on PE Is Technical, Application of the PE
Assessment Tools Takes Place in a Multidimensional Plane,
Including Public Policy and Political
Bootman et al. [12] deﬁned PE as “description and analysis of the
costs of drugs to the health care system and the society”.
O’Donnell et al. [13] deﬁned HTA as “a form of policy research
that examines short and long-term consequences of the applica-
tion of a health-care technology”. The Health Technology Assess-
ment International Association deﬁnition for HTA is “the
systematic evaluation of properties, effects or other impacts of
health care interventions” [14]. Based on these varied deﬁnitions,
HTA can be viewed as broadly related to health care in general
and can involve strategies and more aspects; PE is applied health
economics in the narrower area in pharmaceuticals. Regardless
of the deﬁnitions, the successful use of PE or HTA requires a high
degree of subject-speciﬁc knowledge. Discussions among PE
experts, however, can become so technical that they may not
consider other important dimensions of PE such as the implica-
tion of PE on public policy decisions. Therefore, for reason of
simplicity, “PE” is used because this article mainly focuses on
medicines.
When talking about PE for pharmaceuticals, in economics
theory, we are talking about opportunity costs, always making
trade-offs between different options. For example, allocating a
resource to one disease area makes it unavailable for use in other
disease areas. Similarly, if a resource is used for the health care
sector, it cannot be used for education or housing. In daily life,
policymakers always make these trade-offs by prioritizing the
use of limited resources. Providing resources to care for one or
two individuals is typically a technical decision; however, decid-
ing the use of limited public resources to care for the health of a
country’s populations is certainly a political decision that is likely
highly politically charged.
In addition, setting up a proper legal framework to provide
legal positions for the application of PE is important, and can also
be quite political. Recent examples from Europe are the process
by which requirements of cost-effectiveness analysis were incor-
porated into the Social Security Law in France, and similarly in
Spain, the Royal Decree Law addressed the issue of cost-
effectiveness analysis (CEA) for reimbursing new medications[15,16]. Another example with a long history in the legal frame-
work is found in Australia where Pharmaceutical Beneﬁts Advi-
sory Committees were set up in 1950 s [17]. This is important for
at least two reasons: ﬁrst, ensuring transparency in the PE
process for all stakeholders; second, denying access to innovative
technologies, especially those developed in other countries, could
have an impact on trade treaties between countries. Therefore,
the use of PE to assist decisions on drug reimbursement can go
beyond the health care sector. Unless one has the legal frame-
work moving in the right direction, one cannot properly imple-
ment PE evaluations in technical areas, such as setting up
guidelines or criteria in conducting PE assessments.Involvement in Decision Making Should Be Inclusive for All
Stakeholders
Because the use of PE is very complex, assessment of innovative
technologies by these approaches certainly should involve not
only experts on PE and policymakers but also other stakeholders.
These stakeholders would comprise health care providers,
patients and patient groups, and the pharmaceutical industry.
Involvement of these stakeholders provides different perspec-
tives that will contribute to the overall evolution of PE evalua-
tions. Currently, Taiwan and South Korea are actively engaging
experts in PE and clinicians (physicians and pharmacists)
together with government decision makers in their PE assess-
ments. Later, other stakeholders, such as patient groups, become
involved in this process. However, both these countries are
lagging in their active integration of pharmaceutical industry
representatives (the source of the clinical trial and PE data) into
the process.
Two important considerations should be kept in mind in
regard to stakeholder involvement. The ﬁrst is that having a
dialogue does not mean that there has to be agreement at all
times and active discussion is a key part of the process of
implementing PE. The second is the importance of early engage-
ment of all stakeholders, something that is necessary for sufﬁ-
cient consultation prior to making ﬁnal decisions. In the political
world, especially with Asian cultures, it is important to keep in
mind that once a decision is made, it may take a very long time to
amend that decision. Active and early engagement, therefore, is
key to the successful use of PE evaluations in decision making.Keeping Patients in Mind Is Critical for Adopting Innovative
Technologies
The use of PE normally involves technical experts because it is a
complex, multidisciplinary science. Keeping the patient in mind,
however, is important for any decision making that involves PE
evaluations. A policy decision is always made at the population
level; therefore, when PE assessments are conducted, every
analysis could impact a patient’s life. In other words, we are
not only talking about numbers but also giving information that
will support a decision that would signiﬁcantly impact patients in
our care.
It is well known that in medical practice the ﬂow of
information is usually asymmetrical between clinicians and
patients. The hallmark of a traditional medical practice model
is that clinicians make most of the decisions for patients. In
part, to overcome this one-sided ﬂow of information, in 2009,
US Congress authorized the creation of an institute called the
Patient-Centered Outcomes Research Institute, which is a non-
physician source of information for patients [18]. The goal of
this institute is to provide the best available evidence so that
patients can make informed decisions. Active patient engage-
ment is even regarded as the “blockbuster drug of the century,”
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care in the near future [19].
Getting patients involved in clinical decision making is more
than just having them sign an informed consent form; before
clinical decisions are made, physicians should describe the full
picture of the disease and its treatments to patients, including
the risks and beneﬁts. In the example of Beth Israel Deaconess
Medical Center in the United States, patients have open access to
their records (i.e., the “OpenNotes” Approach). In Asia, patient
participation in medical decision making is in its infancy and the
patients’ voice is relatively weak. This is probably due to Asian
cultures in which patients usually have little inﬂuence on
medical decisions, either at the individual level or at the pop-
ulation level. This situation, however, is changing in part because
of information exchanges via the Internet. Patient groups are
emerging in Taiwan and South Korea [20], and organizations for
patient care are also developing in mainland China. Similar to
other parts of the world, patients in Asia are playing an increas-
ingly important role in making decisions regarding their health
care. Therefore, when talking about developing PE to assist
decision making of health care policy in Asia, we should keep
in mind this important recent evolution in Asian medical
practice.
Although the number of patient groups has grown, obtaining
their perspectives to help inform PE decision making remains
challenging in Asia as well as worldwide. Therefore, setting up
the proper infrastructure and to keep communication ﬂowing
between patient groups and policy decision making is critical.
One practical way to accomplish this is to have patient repre-
sentatives on committees that would provide advice to an HTA
body, such as the formal consultation to the consumer commun-
ity in the United Kingdom and Australia [21].
Two more items are worth mentioning. First, PE decisions
may impact not only patients but also their caregivers; this would
be particularly true for cancer patients and/or elderly patients
with chronic diseases. A recent report on caregivers shows that
this group tends to also experience caregiver burden and related
medical issues such as depression, which generate physician
visits and hospitalizations. This is probably due to, at least for
some cases, the fact that these caregivers have to deal with
depressing situations with their family members or signiﬁcant
others [22]. Second, PE evaluations should not be conducted at
the expense of delaying innovative technologies and medicines
for patients. For example, under the current pricing evaluation
system in Japan, the listing of a price for a newly approved
medicine is normally provided within 2 to 3 months. Whether
this time frame could still be maintained in Japan after an HTA
process is implemented seems challenging.
Focusing on Overall Health Care Beneﬁts Rather Than Drug
Costs Only
When discussing PE assessment for new innovative pharmaceut-
ical products, we are discussing the overall value of those
medicines; the focus is not on the price of the medicines except
in the case of pure cost minimization analysis, where the health
outcomes associated with the new medicine are similar as those
with the comparator medicine. For example, there are 12 million
patients with various tumors living in the United States. In 2011,
the American Society of Clinical Oncology identiﬁed 12 oncology
treatments that have the potential to reduce cancer mortality, of
which 10 involved new medicines. As another example, the
annual rate of death from HIV/AIDS was reported as 16.2% before
highly active antiretroviral theraphy (HAART) therapy was intro-
duced in 1996. In 2010, the HIV/AIDS-related mortality rate had
been reduced to 2.7% [21]. Similarly, studies in Asia found not
only reductions in HBV-related complications due to bettercontrol by new medications but also lower health care costs
[23–25]. These are good examples of how innovative medicines
can beneﬁt patients, the health care system, and society, both
clinically and economically.
As mentioned earlier, an HTA system can have various
formats with or without formal assessment requirements on
CEA. In a number of HTA systems, both CEA and budget impact
analysis (BIA) would be required by an authority when a prod-
uct’s manufacturer applies for pricing and/or reimbursement
status. While a cost-effectiveness model would take into consid-
eration all costs (depending on the perspective) and clinical
efﬁcacy (or effectiveness), a BIA, most of the time, would assess
only pharmacy costs. Even though a BIA is built for the purpose of
understanding the ﬁnancial impact of an additional innovative
medicine on a formulary for reimbursement, using BIA to
evaluate pharmacy costs may be less helpful to comprehensively
oversee and manage health care costs. Therefore, the pros and
cons of using both CEA and BIA should be carefully examined and
balanced when making health care policy.
The Need to Consider Local Country-Speciﬁc Characteristics
When Using PE to Evaluate New Medical Technologies
The creation of Value in Health Regional Issues is a good indicator of
the increasing number of publications on PE in Asia. Because the
concepts and principles of PE were created originally in the
Western world, the concept should be tailored to the socio-
economic situations, health care systems, medical practices,
cultures, and value systems of different Asian countries.
Adoption of PE assessments into population health care
coverage decisions requires the followings: adequate under-
standing of the technical areas and sufﬁcient number of
qualiﬁed researchers or scholars to perform the analysis. A
typical example to illustrate the ﬁrst point is the application of
quality-adjusted life-years (QALYs) when used as a measure of
effectiveness across therapeutic areas or conditions in a CEA.
While it is not that difﬁcult to apply the principle of CEA, it is
quite challenging to decide how to apply the concept of the
QALY in Asia. Health economists in the United Kingdom and
Australia, who are culturally similar, may argue that the QALY
is a straightforward numeric and objective measure to apply;
however, properly generating this number in Asia is challenging
because this is affected by local culture and value systems. The
value of a QALY as derived from the Western world is always
perceived as too high for developing countries, including those
in Asia. As an alternative to the commonly cited value for QALY
used in the United States or the United Kingdom, a two-time
multiple of the country’s annual GDP was proposed by the
World Health Organization [26]. Even if this alternative was
applied in Asia, it would still be tough to use a single value for
all diseases or conditions, and for an entire population. The
recent discussion in the National Institute for Health and
Clinical Excellence around an alternative cancer-speciﬁc QALY
for oncology patients could serve as a good example of how
challenging this can be even in countries such as the United
Kingdom in which QALY analysis is well established [26]. Asia is
no exception to this situation. Therefore, while mathematical
analysis may be feasible, criteria for evaluating certain PE-
related outcomes need to be made on the basis of local
situations.
Because research on PE in Asia is still in its early stage of
development relative to the Western world [27], use of results
from studies outside that did not include Asian countries may
need to be viewed with caution because they may not be
applicable or generalizable to at least some (if not all) of the
countries. A medication that may reduce the length of hospital
stays in the United States would show potential cost saving in
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ization can be expensive. For example, annual costs of hospital-
izations for preterm or low-birth-weight babies can be as high as
$5.1 billion in the United States [28]. Yet, because of differences in
the health care cost structure in Asian countries compared with
the United States, results from US analysis may not be applicable
to Asian health care systems and caution is required when US
data are referenced in Asia.
Proper use of PE also requires qualiﬁed researchers or scholars
who are good in both technical know-how and understanding of
local cultures and health care systems. Both the consideration of
country-speciﬁc characteristics and the availability of knowl-
edgeable PE researches are equally important for the successful
incorporation of innovative technologies into population health
coverage in Asia.Conclusions
Incorporating innovative technologies, in medicines in this
case, into health care coverage in Asia is a double-edge sword:
on the one hand, Asian countries can learn a lot from the
experiences of the Western world, which may shorten the
learning curve; on the other hand, the experiences and ﬁndings
from the Western world may not be directly applicable to Asian
countries; therefore, the applications need to be tailored to
speciﬁc local cultures and health care systems. Based on the
development in the last one decade, it is clear that the concepts
of PE have been extensively introduced to facilitate decision
making for health care resources in Asia. This is also recog-
nition of the core value of innovative technologies that are
relevant to Asian patients and health systems, which will be the
key for future developments.
On the basis of the discussions above, authors of this article
predict that PE research as a whole would become more
extensive. Collaboration on PE academic research will be fur-
ther developed at the regional level. How to apply PE method-
ology developed in the Western world will continue being the
theme in research in Asia. HTA agencies would set up their
evaluation criteria, including a process, on a model based on
experiences from various countries. Different from the aca-
demic research, government agencies in Asia may be more in
favor of practical solutions to policy issues, such as how to
handle budget impacts in the short term. Although value still
needs to be further deﬁned in an empirical sense by various
Asian countries, a value-based price for pharmaceuticals will
become a hot topic. This may be a good opportunity to have a
win-win dialogue between the decision makers and the phar-
maceutical industry. As the overall economy continues to grow,
patient-reported outcomes, including quality of life, will receive
more attention during the policy-making process. Eventually,
proper applications of PE, especially when research is trans-
ferred into health care policy, can be made only at the
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